Skip to main content
. 2016 Nov 28;6(1):89–99. doi: 10.1002/cam4.966

Figure 2.

Figure 2

Volumes of cloudy‐enhancing and solid‐enhancing compartments during treatment. Patients with >21.4% decrease in the cloudy‐enhancing compartment at first follow‐up (A), and patients with <21.4% decrease in the cloudy‐enhancing compartment at first follow‐up (B). TP of tumor progression according to RANO is indicated with a dotted vertical line. Note, that patients of group A had a progression‐free survival (PFS) of at least 7 months (TP5). In contrast, most of the patients of group B had shorter PFS. The necrotic tumor of patient 5 was not progressive according to RANO because it was not measurable.